Answers are grounded in this paper and cite their sources.
Identifies RNA-binding protein biomarkers in esophageal cancer, suggesting therapeutic targets.
Background Esophageal cancer (ESCA) is highly prevalent globally, but the role of RNA-binding proteins (RBPs) in it remains unclear. Methods ESCA datasets were analyzed to identify differentially expressed genes (DEGs). Candidates were derived by intersecting DEGs with RBP-related genes and validated via machine learning, expression analysis, and receiver operating characteristic (ROC) curves. Prognostic value, functional enrichment, immune microenvironment, regulatory networks, drug prediction, and Eca-109 cell validation were assessed. Results Four biomarkers (CDC20, COL7A1, DNMT3B, UBE2T) were confirmed. Low UBE2T/DNMT3B correlated with better survival. In addition, CDC20/UBE2T were linked to DNA replication; COL7A1/DNMT3B to olfactory transduction. Immune analysis showed 15 cell types differed significantly, with most chemokines negatively correlating with biomarkers. Conclusions COL7A1, DNMT3B, and UBE2T were associated with transcription factor TET1. The four biomarkers corresponded to 79, 26, 67, and 23 targeted drugs, respectively, and all were highly expressed in Eca-109 cells, advancing insights into RBP-related mechanisms in ESCA.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: